157 related articles for article (PubMed ID: 36321789)
21. Autoantibody response to Sui1 and its tissue-specific expression in hepatocellular carcinoma.
Zhou JW; Li Y; Yue LX; Luo CL; Chen Y; Zhang JY
Tumour Biol; 2016 Feb; 37(2):2547-53. PubMed ID: 26386724
[TBL] [Abstract][Full Text] [Related]
22. Latent transforming growth factor-beta binding protein-1 in circulating plasma as a novel biomarker for early detection of hepatocellular carcinoma.
Cao B; Yang L; Rong W; Feng L; Han N; Zhang K; Cheng S; Wu J; Xiao T; Gao Y
Int J Clin Exp Pathol; 2015; 8(12):16046-54. PubMed ID: 26884881
[TBL] [Abstract][Full Text] [Related]
23. Circulating miR-21 serves as a serum biomarker for hepatocellular carcinoma and correlated with distant metastasis.
Guo X; Lv X; Lv X; Ma Y; Chen L; Chen Y
Oncotarget; 2017 Jul; 8(27):44050-44058. PubMed ID: 28477010
[TBL] [Abstract][Full Text] [Related]
24. Autoantibodies to PAX5, PTCH1, and GNA11 as Serological Biomarkers in the Detection of Hepatocellular Carcinoma in Hispanic Americans.
Qiu C; Ma Y; Wang B; Zhang X; Wang X; Zhang JY
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835134
[TBL] [Abstract][Full Text] [Related]
25. A cancer-related protein 14-3-3ΞΆ is a potential tumor-associated antigen in immunodiagnosis of hepatocellular carcinoma.
Liu M; Liu X; Ren P; Li J; Chai Y; Zheng SJ; Chen Y; Duan ZP; Li N; Zhang JY
Tumour Biol; 2014 May; 35(5):4247-56. PubMed ID: 24390614
[TBL] [Abstract][Full Text] [Related]
26. Diagnostic value of 5 serum biomarkers for hepatocellular carcinoma with different epidemiological backgrounds: A large-scale, retrospective study.
Liu D; Luo Y; Chen L; Chen L; Zuo D; Li Y; Zhang X; Wu J; Xi Q; Li G; Qi L; Yue X; Zhang X; Sun Z; Zhang N; Song T; Lu W; Guo H
Cancer Biol Med; 2021 Feb; 18(1):256-270. PubMed ID: 33628599
[TBL] [Abstract][Full Text] [Related]
27. Humoral autoimmune response to nucleophosmin in the immunodiagnosis of hepatocellular carcinoma.
Liu M; Varela-Ramirez A; Li J; Dai L; Aguilera RJ; Zhang JY
Oncol Rep; 2015 May; 33(5):2245-52. PubMed ID: 25779011
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of squamous cell carcinoma antigen-immunoglobulin M complex (SCCA-IGM) and alpha-L-fucosidase (AFU) as novel diagnostic biomarkers for hepatocellular carcinoma.
Mossad NA; Mahmoud EH; Osman EA; Mahmoud SH; Shousha HI
Tumour Biol; 2014 Nov; 35(11):11559-64. PubMed ID: 25129443
[TBL] [Abstract][Full Text] [Related]
29. Development and application of a fluorescence protein microarray for detecting serum alpha-fetoprotein in patients with hepatocellular carcinoma.
Zhang A; Yin C; Wang Z; Zhang Y; Zhao Y; Li A; Sun H; Lin D; Li N
J Int Med Res; 2016 Dec; 44(6):1414-1423. PubMed ID: 27885040
[TBL] [Abstract][Full Text] [Related]
30. Serum Dickkopf-1 as a Biomarker for the Diagnosis of Hepatocellular Carcinoma.
Kim SU; Park JH; Kim HS; Lee JM; Lee HG; Kim H; Choi SH; Baek S; Kim BK; Park JY; Kim DY; Ahn SH; Lee JD; Han KH
Yonsei Med J; 2015 Sep; 56(5):1296-306. PubMed ID: 26256972
[TBL] [Abstract][Full Text] [Related]
31. Glypican-3 level assessed by the enzyme-linked immunosorbent assay is inferior to alpha-fetoprotein level for hepatocellular carcinoma diagnosis.
Jeon Y; Jang ES; Choi YS; Kim JW; Jeong SH
Clin Mol Hepatol; 2016 Sep; 22(3):359-365. PubMed ID: 27729630
[TBL] [Abstract][Full Text] [Related]
32. Soluble Axl Is a Novel Diagnostic Biomarker of Hepatocellular Carcinoma in Chinese Patients with Chronic Hepatitis B Virus Infection.
Song X; Wu A; Ding Z; Liang S; Zhang C
Cancer Res Treat; 2020 Jul; 52(3):789-797. PubMed ID: 32138467
[TBL] [Abstract][Full Text] [Related]
33. Combination of miR-125b and miR-27a enhances sensitivity and specificity of AFP-based diagnosis of hepatocellular carcinoma.
Zuo D; Chen L; Liu X; Wang X; Xi Q; Luo Y; Zhang N; Guo H
Tumour Biol; 2016 May; 37(5):6539-49. PubMed ID: 26637228
[TBL] [Abstract][Full Text] [Related]
34. Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: a large-scale, multicentre study.
Shen Q; Fan J; Yang XR; Tan Y; Zhao W; Xu Y; Wang N; Niu Y; Wu Z; Zhou J; Qiu SJ; Shi YH; Yu B; Tang N; Chu W; Wang M; Wu J; Zhang Z; Yang S; Gu J; Wang H; Qin W
Lancet Oncol; 2012 Aug; 13(8):817-26. PubMed ID: 22738799
[TBL] [Abstract][Full Text] [Related]
35. Combination of exosomes and circulating microRNAs may serve as a promising tumor marker complementary to alpha-fetoprotein for early-stage hepatocellular carcinoma diagnosis in rats.
Liu WH; Ren LN; Wang X; Wang T; Zhang N; Gao Y; Luo H; Navarro-Alvarez N; Tang LJ
J Cancer Res Clin Oncol; 2015 Oct; 141(10):1767-78. PubMed ID: 25724413
[TBL] [Abstract][Full Text] [Related]
36. Serum anti-osteopontin autoantibody as a novel diagnostic and prognostic biomarker in patients with hepatocellular carcinoma.
Ying X; Zhao Y; Wang JL; Zhou X; Zhao J; He CC; Guo XJ; Jin GH; Wang LJ; Zhu Q; Han SX
Oncol Rep; 2014 Oct; 32(4):1550-6. PubMed ID: 25109745
[TBL] [Abstract][Full Text] [Related]
37. AFP, PIVKAII, GP3, SCCA-1 and follisatin as surveillance biomarkers for hepatocellular cancer in non-alcoholic and alcoholic fatty liver disease.
Beale G; Chattopadhyay D; Gray J; Stewart S; Hudson M; Day C; Trerotoli P; Giannelli G; Manas D; Reeves H
BMC Cancer; 2008 Jul; 8():200. PubMed ID: 18638391
[TBL] [Abstract][Full Text] [Related]
38. A simple diagnostic index comprising epithelial membrane antigen and fibronectin for hepatocellular carcinoma.
Attallah AM; El-Far M; Abdel Malak CA; Farid K; Omran MM; Yahya RS; Saad EA; Albannan MS; Attallah AA; El Basuni MA; Ali IS; Abed SB; El Naggar MA
Ann Hepatol; 2015; 14(6):869-80. PubMed ID: 26436359
[TBL] [Abstract][Full Text] [Related]
39. Annexin A2 is a discriminative serological candidate in early hepatocellular carcinoma.
Sun Y; Gao G; Cai J; Wang Y; Qu X; He L; Liu F; Zhang Y; Lin K; Ma S; Yang X; Qian X; Zhao X
Carcinogenesis; 2013 Mar; 34(3):595-604. PubMed ID: 23188673
[TBL] [Abstract][Full Text] [Related]
40. Serum fibroblast growth factor 19 serves as a potential novel biomarker for hepatocellular carcinoma.
Maeda T; Kanzaki H; Chiba T; Ao J; Kanayama K; Maruta S; Kusakabe Y; Saito T; Kobayashi K; Kiyono S; Nakamura M; Ogasawara S; Suzuki E; Ooka Y; Nakamoto S; Nakagawa R; Muroyama R; Kanda T; Maruyama H; Kato N
BMC Cancer; 2019 Nov; 19(1):1088. PubMed ID: 31718608
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
